15th INTERNATIONAL CONGRESS OF PARKINSON'S

Abstracts by Topic
166 Movement disorders in adult patients with classical galactosemia
I. Rubio-Agusti, M. Carecchio, R. Lachmann, M.J. Edwards,
E. Murphy, K.P. Bhatia (London, United Kingdom)
167 Characteristics of a Parkinson’s disease cohort and five years follow
up in a Buenos Aires city hospital in Argentina
J.P. Tartari, C.V. Stefani, D.J. Bauso, J.I. Rojas, E. Cristiano (Buenos
Aires, Argentina)
168 Past exposure to dopaminergic receptor blocking drugs and the risk
of idiopathic Parkinson’s disease
A. Foubert-Samier, C. Helmer, F. Perez, M. Le Goff, S. Auriacombe,
A. Elbaz, J.-F. Dartigues, F. Tison (Bordeaux, France)
169 Prevalence of orthostatic hypotension in Parkinson’s disease: A
systematic review and meta-analysis
D.C. Velseboer, R.J. de Haan, W. Wieling, D.S. Goldstein, R.M. de Bie
(Amsterdam, NH, Netherlands)
170 Mortality in Parkinson’s disease patients in Tanzania
C.L. Dotchin, O. Msuya, R. Amarro, J. Massawe, A.M. Jusabani,
R.W. Walker (North Shields, Tyne and Wear, United Kingdom)
Gene Therapies and Cell-based Therapies
171 NGF has a role in the potentiation of neuroregeneration in a mouse
model of Huntington’s disease
L.-W. Chen, L.-Y. Horng, C.-L. Wu, C.-H. Wu, Y.-S. Zheng, H.-
C. Sung, R.-T. Wu (Taipei, Taiwan)
172 Why is GDNF not protective in the alpha-synuclein model of
Parkinson’s disease?
M. Decressac, B. Mattsson, A. Bjorklund (Lund, Sweden)
173 Transplantation of retinal pigment epithelial (RPE) cells restores
motor coordination in the rat model of Parkinson’s disease (PD)
H.S. Gambhir, S. Vivekanandhan, V. Goyal, R. Mathur, M. Behari
(New Delhi, Delhi, India)
174 Withdrawn by Author
Huntington’s disease
175 The influence of neuropsychiatric symptoms on functional disability
in Huntington’s disease
K. Banaszkiewicz, M. Bielanska, E. Klimiec, D. Nieweglowska,
M. Banach, M. Rudzinska, A. Szczudlik (Krakow, Poland)
176 Parkinsonian signs in Huntington’s disease patients
K. Banaszkiewicz, E. Klimiec, P. Moskal, M. Rudzinska, A. Szczudlik
(Kraków, Poland)
177 Neuroprotective effect of gabapentin and lamotrigine against
3-nitropropionic acid induced animal models of Huntington’s
disease’
P.K. Bnasal, H. Kalonia, A. Kumar (Chandigarh, India)
178 A longitudinal investigation of mattis dementia rating scale subscale
scores in individuals with manifest Huntington’s disease
D. Brown, J. Bansberg, J. Goldstein, E. Pirogovsky, S. Gluhm, J. Corey-
Bloom, P.E. Gilbert (San Diego, California, USA)
179 Late-stage Huntington’s disease (HD): A cohort from the European
Huntington’s disease network
M. Coelho, T. Mestre, J.J. Ferreira, EHDN Investigators (Lisbon,
Portugal)
15 th INTERNATIONAL CONGRESS OF PARKINSON’S
DISEASE AND MOVEMENT DISORDERS
180 Caffeine is a modifier of age at onset in Huntington’s disease
C. Duru, C. Simonin, F. Richard, P. Hincker, J. Salleron, P. Charles,
K. Youssov, S. Burnouf, J.-P. Azulay, C. Verny, C. Tranchant, C. Goizet,
L. Defebvre, B. Sablonniere, M. Romon, L. Buee, P. Amouyel,
O. Godefroy, A. Durr, A.-C. Bachoud-Levi, D. Blum, P. Krystkowiak,
On Behalf the Huntington French Speaking Network (Amiens, France,
Metropolitan)
181 Changes in the expression of the striatal-enriched protein tyrosine
phosphatase and of extracellular regulated kinase in the R6/2 mouse
model of Huntington’s disease
F. Fusco, S. Anzilotti, C. Giampa, D. Laurenti, G. Bernardi, M. Melone
(Rome, Italy)
182 Apathy in Huntington’s disease from an Argentinean series of cases
A. Bottini Bonfanti, V. Parisi, G. Persi, J. Etcheverry, E. Gatto (,
Argentina)
183 Verbal working memory deficits in prodromal Huntington’s disease
J. Gooblar, K. Possin, G. Kang, L. Gritzer, A. Berhel, M. Geschwind,
B.L. Miller, C.P. Hess, J.H. Kramer (San Francisco, California, USA)
184 Pallidal deep brain stimulation (DBS) in Chorea Huntington:
Preliminary results of a phase I trial
V. Jan, W. Lars, W. Christian, S. Alfons (Duesseldorf, Germany)
185 A clinical and genetic profile of 17 patients with Huntington’s disease
seen in Southern India
K.R. Jhavar, P.K. Pal, M.S. Nagaraj, R. Yadav, S. Jain, J. Saini,
M. Purushottam (Bangalore, Karnataka, India)
186 Targeting oxidative stress attenuates malonic acid induced
Huntington like behavioral and mitochondrial alterations in rats
H. Kalonia, A. Kumar (Chandigarh, India)
187 Earliest disfunction in Huntington ‘s disease
F. Moreira, C. Nunes, F. Júlio, C. Januário (Coimbra, Portugal)
188 Long term effects induced by quadripulse stimulation in
Huntington’s disease
S. Ohminami, Y. Terao, Y. Shirota, R. Tsutsumi, J. Goto, Y. Ichikawa,
S. Tsuji, Y. Ugawa, R. Hanajima (Bunkyo-ku, Tokyo, Kanto, Japan)
189 Gait variability increases with proximity to diagnosis in prodromal
Huntington’s disease: Longitudinal quantitative gait analysis
A.K. Rao, E.D. Louis, K.S. Marder (New York, New York, USA)
190 Novel “bottom-up” recruiting strategies for a Huntington’s disease
clinical trial at Evergreen Neuroscience Institute, a new HSG
investigative site lacking a patient base
P. Agarwal, C.C. Sia, L.V. Goodman (Kirkland, Washington, USA)
191 Abnormal apocrine sweat gland mitochondria in Huntington’s
disease
C. Sidiropoulos, P. LeWitt, K. Hashimoto (Detroit, Michigan, USA)
192 Brain glucose hypometabolism in a subject carrying an unstable
allele of intermediate CAG 33 repeat length in the Huntington’s
disease gene
F. Squitieri, M. Esmaeilzadeh, A. Ciarmiello, J. Jankovic (Pozzilli, Italy)
193 Functional rating scale taskforce for pre-Huntington’s disease
(FuRST-pHD): An initiative to develop a gold standard instrument
to assess early manifestations of Huntington’s disease (HD)
A.L. Vaccarino, K.E. Anderson, B. Borowsky, J. Giuliano, M. Guttman,
A.K. Ho, J.S. Paulsen, T. Sills, D.P. van Kammen, K.R. Evans (Toronto,
Canada)
TORONTO
91
June 5–9, 2011 Toronto, ON, C anada
Abstracts
by topic